Concepción A. U.
- Country
- Spain
- Department
- Hematología
Research Overview
- Phase III Trial Comparing Extended Lenalidomide-Bortezomib-Dexamethasone with Early Rescue vs. Isatuximab-Lenalidomide-Bortezomib-Dexamethasone vs. Isatuximab-Lenalidomide-Iberdomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Candidates for Autologous Stem Cell Transplantation
- Efficacy and Safety Evaluation of Depemokimab in Adults with Hypereosinophilic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
- Phase 3 Double-Blind Randomized Study of Lisaftoclax (APG-2575) and Azacitidine in Newly Diagnosed Higher-Risk Myelodysplastic Syndrome Patients
Data & Insights
Has run more than one trial at 16 of 144 partner sites.
Specializations
Hematologic Malignancies
Clinical activity in multiple myeloma, including newly diagnosed multiple myeloma, refractory or relapsed multiple myeloma, and relapsed or refractory multiple myeloma, with additional involvement in acute myeloid leukemia and higher-risk myelodysplastic syndrome. The research profile also includes treatment strategies for patients considered for autologous stem cell transplantation and evaluation of minimal residual disease response.
- Multiple myeloma management
- Myelodysplastic syndrome
- Acute myeloid leukemia
- MRD-directed treatment assessment
This area reflects a strong focus on plasma cell disorders and advanced hematology care in Madrid.
Allergic and Eosinophilic Disease
Research involvement extends to hypereosinophilic syndrome and allergic rhinitis with rhinoconjunctivitis, including patients with associated allergic asthma. The therapeutic landscape also covers seasonal pollen-related disease control and allergen immunotherapy for grass and cupressaceae sensitization.
- Hypereosinophilic syndrome
- Allergic rhinitis and rhinoconjunctivitis
- Allergic asthma
- Allergen immunotherapy
These studies place emphasis on immune-mediated airway and eosinophilic conditions managed within a clinical trial setting.
Novel Therapies in Plasma Cell Disorders
Participation in trials for first-in-human and comparative approaches in plasma cell disorders highlights interest in emerging therapeutic options for multiple myeloma. The research scope includes bispecific or targeted antibody-based therapies, as well as combination treatment strategies designed to improve depth of response in relapsed disease.
- Innovative anti-myeloma agents
- Antibody-based combinations
- Relapsed disease treatment
- Response optimization
Work in this domain supports therapeutic development for patients with difficult-to-treat hematologic cancers.
Myeloid Neoplasms and Targeted Combinations
Clinical research also includes newly diagnosed acute myeloid leukemia and higher-risk myelodysplastic syndrome, with attention to combination regimens that integrate venetoclax, azacitidine, and quizartinib. This area is centered on improving outcomes for patients who are not eligible for conventional intensive induction therapy.
- Acute myeloid leukemia combinations
- Venetoclax-based therapy
- Azacitidine combinations
- Targeted myeloid treatment
The therapeutic focus remains on advancing options for myeloid malignancies with limited standard treatment pathways.
Respiratory Oncology
In advanced/metastatic non-squamous non-small cell lung cancer, the investigator is involved in studies evaluating immunotherapy biosimilars and treatment comparability in thoracic oncology. This domain links systemic cancer treatment with access-oriented development of biologic therapies.
- Non-small cell lung cancer
- Metastatic solid tumors
- Immunotherapy biosimilars
- Thoracic oncology
This adds a solid-tumor dimension to a predominantly hematologic and allergy/immunology-focused research portfolio.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.